AbbVie | ABBV - Gross Profit On Sales



AbbVie reported $9.34B in Gross Profit on Sales for its fiscal quarter ending in March of 2025.


Gross Profit On Sales Change Date
AbbVie USD 9.34B 1.36B Mar/2025
Abbott USD 5.87B 50M Jun/2025
ALKERMES USD 257.77M 462K Jun/2025
Amgen USD 6.17B 624M Jun/2025
AstraZeneca USD 11.98B 637M Jun/2025
Biogen USD 2.04B 238.8M Jun/2025
BioMarin Pharmaceutical USD 670.47M 76.89M Jun/2025
Bristol-Myers Squibb USD 8.9B 714M Jun/2025
Eisai JPY 160.05B 12.42B Jun/2025
Eli Lilly USD 13.11B 2.61B Jun/2025
Gilead Sciences USD 5.58B 453M Jun/2025
GlaxoSmithKline GBP 5.82B 229M Jun/2025
J&J USD 14.6B 816M Mar/2025
Medtronic USD 5.12B 695M Jul/2025
Merck USD 12.99B 224M Jun/2025
Neurocrine Biosciences USD 676.2M 112.8M Jun/2025
Novartis USD 11.51B 1.12B Jun/2025
Pacira USD 125.91M 8.71M Jun/2025
Perrigo USD 362.9M 29.4M Jun/2025
Pfizer USD 10.88B 248M Jun/2025
Regeneron Pharmaceuticals USD 3.15B 581M Jun/2025
Roche Holding CHF 11.69B 48M Dec/2024
Sanofi EUR 7.74B 26M Jun/2025
UCB EUR 2.46B 520M Dec/2024
Ultragenyx Pharmaceutical USD 143.49M 32.86M Jun/2025
United Therapeutics USD 711M 9.1M Jun/2025
Vertex Pharmaceuticals USD 2.56B 150M Jun/2025
Zoetis USD 1.78B 180M Jun/2025